Evaluation of Colocasia esculenta Schott in anti-cancerous properties with proximity extension assays

  • Liang Wu Jiangsu Key Laboratory of Drug Screening, China Pharmaceutical University, Nanjing; and Department of Pharmacology, China Pharmaceutical University, Nanjing, China
  • Yuxuan Wang Jiangsu Key Laboratory of Drug Screening, China Pharmaceutical University, Nanjing, China
  • Xiaoyan Wang Jiangsu Key Laboratory of Drug Screening, China Pharmaceutical University, Nanjing, China
  • Jun Liao School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, China
  • Hao Dong Jiangsu Key Laboratory of Drug Screening, China Pharmaceutical University, Nanjing, China
  • Xiyunyi Cai Jiangsu Key Laboratory of Drug Screening, China Pharmaceutical University, Nanjing, China
  • Yurong Wang School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, China
  • Harvest F. Gu School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, China
DOI: https://doi.org/10.29219/fnr.v65.7549
Keywords: Colocasia esculenta Schott; Metabolism; Oncology, Proximity Extension Assay

Abstract

Background: Colocasia esculenta Schott (called as Xiangshayu in Chinese) is an excellent local cultivar of the genus polymorpha in Jiangsu Province, China.

Objective: In the present study, we have performed a comparative study before and after dietary consumption with Colocasia esculenta Schott to evaluate its anti-cancerous properties.

Design: Forty-two healthy volunteers were recruited, and dietary consumption with 200 g of tap water cooked Colocasia esculenta Schott daily was conducted for 1 month. Plasma samples from the subjects before and after dietary consumption with Colocasia esculenta Schott were analyzed with proximity extension assays for the alteration of 92 proteins in relation with cancers, while blood samples were examined for physiological parameters with an automatic biochemical analyzer. Bioinformatic analyses were conducted using MalaCards and GEPIA.

Results: After taking dietary consumption with Colocasia esculenta Schott, circulating CYR61, ANXA1, and VIM protein levels in the subjects was found to be most significantly downregulated, while for ITGB5, EPHA2, and CEACAM1, it was upregulated. Alternation of these proteins was predicted to be associated with the development of tumors such as pancreatic adenocarcinoma and breast and prostate cancers.

Conclusion: The present study provides evidence that Colocasia esculenta Schott, as a healthy food, has anti-cancerous properties. Further investigation of phytochemistry in Colocasia esculenta Schott has been taken into our consideration.

Downloads

Download data is not yet available.

References


  1. Landis-Piwowar KR, Iyer NR. Cancer chemoprevention: current state of the art. Cancer Growth Metastasis 2014; 7: 19–25. doi: 10.4137/CGM.S11288
  2. Chen AY, Chen YC. A review of the dietary flavonoid, kaempferol on human health and cancer chemoprevention. Food Chem 2013; 138(4): 2099–107. doi: 10.1016/j.foodchem.2012.11.139
  3. Park HR, Lee HS, Cho SY, Kim YS, Shin KS. Anti-metastatic effect of polysaccharide isolated from Colocasia esculenta is exerted through immunostimulation. Int J Mol Med 2013; 31(2): 361–8. doi: 10.3892/ijmm.2012.1224
  4. Brown AC, Reitzenstein JE, Liu J, Jadus MR. The anti-cancer effects of poi (Colocasia esculenta) on colonic adenocarcinoma cells in vitro. Phytother Res 2005; 19(9): 767–71. doi: 10.1002/ptr.1712
  5. Kundu N, Campbell P, Hampton B, Lin CY, Ma X, Ambulos N, et al. Antimetastatic activity isolated from Colocasia esculenta. Anticancer Drugs 2012; 23(2): 200–11. doi: 10.1097/CAD.0b013e32834b85e8
  6. Yin J, Han X, Wang L, Zhang P, Guo W, Li C. Dynamic characteristics of growth and development of Colocasia esculenta Schott in Jingjiang. Agr Sci Tech 2014, 3:375–8.
  7. Gullberg M, Fredriksson S, Taussig M, Jarvius J, Gustafsdottir S, Landegren U. A sense of closeness: protein detection by proximity ligation. Curr Opin Biotechnol 2003; 14(1): 82–6. doi: 10.1016/s0958-1669(02)00011-3
  8. Blokzijl A, Nong R, Darmanis S, Hertz E, Landegren U, Kamali-Moghaddam M. Protein biomarker validation via proximity ligation assays. Biochim Biophys Acta 2014; 1844(5): 933–9. doi: 10.1016/j.bbapap.2013.07.016
  9. Andersson E, Lundberg M, Holmquist G, Björkesten J, Thorsen SB, Ekman D, et al. Homogenous 96-plex PEA immunoassay exhibiting high sensitivity, specificity, and excellent scalability. PLoS One 2014; 9(4): e95192. doi: 10.1371/journal.pone.0095192
  10. Cock PJ, Antao T, Chang JT, Chapman BA, Cox CJ, Dalke A, et al. Biopython: freely available Python tools for computational molecular biology and bioinformatics. Bioinformatics 2009; 25(11): 1422–3. doi: 10.1093/bioinformatics/btp163
  11. Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res 2017; 45(W1): W98–W102. doi: 10.1093/nar/gkx247
  12. Andronis C, Sharma A, Virvilis V, Deftereos S, Persidis A. Literature mining, ontologies and information visualization for drug repurposing. Brief Bioinform 2011; 12(4): 357–68. doi: 10.1093/bib/bbr005
  13. Deftereos SN, Andronis C, Friedla EJ, Persidis A, Persidis A. Drug repurposing and adverse event prediction using high-throughput literature analysis. Wiley Interdiscip Rev Syst Biol Med 2011; 3(3): 323–34. doi: 10.1002/wsbm.147
  14. Lundberg M, Eriksson A, Tran B, Assarsson E, Fredriksson S. Homogeneous antibody-based proximity extension assays provide sensitive and specific detection of low-abundant proteins in human blood. Nucleic Acids Res 2011; 39(15): e102. doi: 10.1093/nar/gkr424
  15. Menéndez JA, Mehmi I, Griggs DW, Lupu R. The angiogenic factor CYR61 in breast cancer: molecular pathology and therapeutic perspectives. Endocr Relat Cancer 2003; 10(2): 141–52. doi: 10.1677/erc.0.0100141
  16. Terada N, Kulkarni P, Getzenberg RH. Cyr61 is a potential prognostic marker for prostate cancer. Asian J Androl 2012; 14(3): 405–8. doi: 10.1038/aja.2011.149
  17. Yang R, Chen Y, Chen D. Biological functions and role of CCN1/Cyr61 in embryogenesis and tumorigenesis in the female reproductive system. Mol Med Rep 2018; 17(1): 3–10. doi: 10.3892/mmr.2017.7880
  18. Inokuchi J, Lau A, Tyson DR, Ornstein DK. Loss of annexin A1 disrupts normal prostate glandular structure by inducing autocrine IL-6 signaling. Carcinogenesis 2009; 30(7): 1082–8. doi: 10.1093/carcin/bgp078
  19. Battaglia RA, Delic S, Herrmann H, Snider NT. Vimentin on the move: new developments in cell migration 2018; F1000Res: 7. doi: 10.12688/f1000research.15967.1
  20. Lazarova DL, Bordonaro M. Vimentin, colon cancer progression and resistance to butyrate and other HDACis. J Cell Mol Med 2016; 20(6): 989–93. doi: 10.1111/jcmm.12850
  21. Beauchemin N, Arabzadeh A. Carcinoembryonic antigen-related cell adhesion molecules (CEACAMs) in cancer progression and metastasis. Cancer Metastasis Rev 2013; 32(3–4): 643–71. doi: 10.1007/s10555-013-9444-6
  22. Gray-Owen SD, Blumberg RS. CEACAM1: contact-dependent control of immunity. Nat Rev Immunol 2006; 6(6): 433–46. doi: 10.1038/nri1864
  23. Dankner M, Gray-Owen SD, Huang YH, Blumberg RS, Beauchemin N. CEACAM1 as a multi-purpose target for cancer immunotherapy. Oncoimmunology 2017; 6(7): e1328336. doi: 10.1080/2162402X.2017.1328336
  24. Ieguchi K, Maru Y. Roles of EphA1/A2 and ephrin-A1 in cancer. Cancer Sci 2019; 110(3): 841–8. doi: 10.1111/cas.13942
  25. Zhou Y, Sakurai H. Emerging and diverse functions of the EphA2 noncanonical pathway in cancer progression. Biol Pharm Bull 2017; 40(10): 1616–24. doi: 10.1248/bpb.b17-00446
  26. Lin Z, He R, Luo H, Lu C, Ning Z, Wu Y, et al. Integrin-β5, a miR-185-targeted gene, promotes hepatocellular carcinoma tumorigenesis by regulating β-catenin stability. J Exp Clin Cancer Res 2018; 37(1): 17. doi: 10.1186/s13046-018-0691-9
  27. Gerashchenko TS, Zavyalova MV, Denisov EV, Krakhmal NV, Pautova DN, Litviakov NV, et al. Intratumoral morphological heterogeneity of breast cancer as an indicator of the metastatic potential and tumor chemosensitivity. Acta Naturae 2017; 9(1): 56–67.
  28. Pereira PR, Corrêa ACNTF, Vericimo MA, Paschoalin VMF. Tarin, a Potential immunomodulator and COX-inhibitor lectin found in Colocasia esculenta Schott. Compr Rev Food Sci Food Saf 2018; 17(4): 878–91. doi: 10.1111/1541-4337.12358
Published
2021-10-04
How to Cite
Wu L., Wang Y., Wang X., Liao J., Dong H., Cai X., Wang Y., & Gu H. F. (2021). Evaluation of <em>Colocasia esculenta</em&gt; Schott in anti-cancerous properties with proximity extension assays. Food & Nutrition Research, 65. https://doi.org/10.29219/fnr.v65.7549
Issue
Vol 65 (2021)
Section
Original Articles
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors retain copyright of their work, with first publication rights granted to SNF Swedish Nutrition Foundation. Read the full Copyright- and Licensing Statement.

 

 

Crossref
Scopus
Google Scholar
Europe PMC